A Case of Perampanel Overdose Presenting with Respiratory Failure

Yangmi Park, MD, Seondeuk Kim, MD, Dae Lim Koo, MD, PhD, Hyunwoo Nam, MD, PhD
Department of Neurology, Seoul Metropolitan Government, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea

Introduction

Perampanel is a novel antiepileptic drug that has been used as an adjunctive treatment for focal-onset seizures. It has a long half-life of 105 hours and an oral preparation at a maximum dose of 12 mg/day is considered safe. Clinical trials have shown that perampanel is generally well-tolerated despite inducing dose-dependent adverse events of the central nervous system, such as dizziness, somnolence, irritability, headache, and psychiatric problems. Also, there are two cases with respiratory depression as an adverse events of perampanel in children previously diagnosed with compromised respiratory function. However, no reports to date have documented respiratory suppression as a side effect of perampanel in adults. Herein, we report a case of perampanel overdose with respiratory failure.

Case Report

A 51-year-old man with focal epilepsy visited the emergency department with altered mentality and irritability. The patient had a history of chronic subdural hemorrhage and mental retardation. He originally received perampanel (6 mg/day) and levetiracetam (1,000 mg 2 day). However, we estimated that he had accidentally consumed 66 mg of perampanel 1 hour before visiting our hospital. His parents denied the possibility of seizure provocation, including sleep deprivation, malnutrition, and alcohol consumption. Initially, his blood pressure was as high as 192/92 mmHg, but other signs, including body temperature, heart rate, and respiratory rate, were within the normal range. He also presented with a comatose mentality and roving eye movements without convulsions. Laboratory findings confirmed mild hypercapnia (partial pressure of CO2 [pCO2], 51.3 mmHg) and hypoxemia (partial pressure of O2 [pO2], 55.7 mmHg), and chest radiography revealed no active lung lesion. Moreover, brain computed tomography revealed no acute structural lesions. Electroencephalography showed no epileptiform discharges. At 2.5 hours after arrival at our hospital, his respiratory function deteriorated with aggravation of hypercapnia (62.3 mmHg) and desaturation (saturation of percutaneous O2, 86%) despite O2 supply (Fig. 1A). Because he had type 2 respiratory failure, intubation was performed and the respiratory rate was completely controlled via mechanical ventilation in the range of 13 to 20 times/min in the intensive care unit. Dexmedetomidine and remifentanil was used to control irritability. His Glasgow coma scale (GCS) score had deteriorated because of the increased amount of remifentanil used for controlling his irritability on the first day of hospitalization (hospital day 1). Thereafter, perampanel was replaced with 1,350 mg/day of valproic acid and the dose of levetiracetam was increased from 1,000 mg/day to 2,000 mg/day. After hospital day 2.5,
Park Y, et al. Respiratory Failure after Perampanel Overdose

It induces various adverse events, such as irritability, aggression, and altered consciousness. However, evidence on the significant adverse effects of perampanel on vital signs, electrocardiography measures, and biochemical or hematologic parameters is currently lacking. Kim et al. reported the case of a 39-year-old woman with perampanel overdose (40 mg of perampanel) with a comatose mentality, but her respiratory function was normal. In another case, a man in his 20s with perampanel overdose (42 mg of perampanel) experienced prolonged unconsciousness, but showed no evidence of respiratory compromise. In children, there were two cases of respiratory depression with therapeutic dose of perampanel (0.04 mg/kg and 0.17 mg/kg) respectively, but they had compromised respiratory function before. In our case, perampanel overdose (1.05 mg/kg of perampanel) resulted in acute respiratory failure, which was not associated with other medical conditions. Moreover, unlike in these previous patients, our patient required mechanical ventilator support. Considering the half-life of perampanel is approximately 105 hours, respiratory suppression could be related to perampanel overdose. To the best of our knowledge, this is the first report of respiratory failure caused by acute perampanel overdose. Therefore, the possibility of respiratory compromise should be considered whenever a high dose of perampanel needs to be administered to patients.

Acknowledgements

We have no affiliations with or involvement in any organization or entity with any financial interest, or non-financial interest. The authors report no disclosures.

Conflict of Interest

The authors declare that they have no conflicts of interest.

References